DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

Phase 1

Not yet recruiting

Conditions: CML,Blast Phase

Interventions: Drug: Olverembatinib
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 29

Registration Number: NCT06757855

Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

Phase 3

Not yet recruiting

Conditions: AML
RUNX1-RUNX1T1 Fusion Protein Expression

Interventions: Drug: cytarabine
Drug: daunorubicin
Drug: idarubicin
Drug: cyclophosphamide

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 300

Registration Number: NCT06744504

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

Phase 2

Not yet recruiting

Conditions: AML

Interventions: Drug: daunorubicin
Drug: Venetoclax
Drug: cytarabine
Drug: azacitidine
Drug: Homoharringtonine
Drug: Idarubicin

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 60

Registration Number: NCT06744556

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

Not Applicable

Not yet recruiting

Conditions: High Risk Smoldering Multiple Myeloma

Interventions: Drug: CM336

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06745687

Locations: 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China

CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

Phase 1

Recruiting

Conditions: Autoimmune Hemolytic Anemia
CD19/BCMA CAR T-cells
Universal Allogeneic CAR T-cells

Interventions: Biological: universal allogeneic anti-CD19/BCMA CAR T-cells

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 15

Registration Number: NCT06733610

Locations: 🇨🇳
Regenerative Medicine Center and Red Blood Cell Disorders Center, Tianjin, Tianjin, China

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/refractory Indolent T/NK-cell Lymphomas

Phase 2

Recruiting

Conditions: Lymphoma, T-Cell
NK-LGL Leukemia
T-LGL Leukemia
Cutaneous T Cell Lymphoma
Cutaneous T Cell Lymphoma (CTCL)
Large Granular Lymphocyte Leukemia
Large Granular Lymphocytic Leukemia
Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma
Mycosis Fungoides

Interventions: Drug: JAK1 Inhibitor

First Posted Date: 2024-12-04

Last Posted Date: 2024-12-10

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 48

Registration Number: NCT06716658

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
🇨🇳
Institute of Hematology & Blood Diseases Hospital, China, Tianjin, Tianjin, China

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 1

Not yet recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: linperlisib and SHR2554

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 33

Registration Number: NCT06712173

Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD

Conditions: Invasive Fungal Disease
Graft Versus Host Disease
Hematopoietic Stem Cell Transplantation

Interventions: Drug: Posaconazole tablet

First Posted Date: 2024-11-20

Last Posted Date: 2024-11-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 40

Registration Number: NCT06698211

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia

Phase 2

Recruiting

Conditions: Severe Aplastic Anemia
Cyclophosphamide Reduced-dose
Immunosuppressive Therapy

Interventions: Drug: Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy

First Posted Date: 2024-11-19

Last Posted Date: 2024-11-19

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 75

Registration Number: NCT06695741

Locations: 🇨🇳
Red Blood Cell Disorders Center and Regenerative Medicine Center, Tianjin, Tianjin, China

CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases

Early Phase 1

Not yet recruiting

Conditions: Autoimmune Diseases

Interventions: Drug: Drug：CD19 CAR-T

First Posted Date: 2024-11-08

Last Posted Date: 2024-11-08

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 15

Registration Number: NCT06680388

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy